Vanguard Capital Wealth Advisors Acquires 20 Shares of Eli Lilly and Company (NYSE:LLY)

Vanguard Capital Wealth Advisors increased its holdings in Eli Lilly and Company (NYSE:LLY) by 3.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 565 shares of the company’s stock after purchasing an additional 20 shares during the quarter. Vanguard Capital Wealth Advisors’ holdings in Eli Lilly and Company were worth $440,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of LLY. Versant Capital Management Inc lifted its stake in shares of Eli Lilly and Company by 1.8% in the first quarter. Versant Capital Management Inc now owns 736 shares of the company’s stock worth $573,000 after acquiring an additional 13 shares during the period. Moseley Investment Management Inc. increased its position in shares of Eli Lilly and Company by 0.4% during the first quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company’s stock worth $3,027,000 after buying an additional 14 shares during the period. CGN Advisors LLC raised its stake in Eli Lilly and Company by 1.4% during the first quarter. CGN Advisors LLC now owns 1,001 shares of the company’s stock worth $779,000 after buying an additional 14 shares during the last quarter. Buckhead Capital Management LLC lifted its holdings in Eli Lilly and Company by 0.7% in the fourth quarter. Buckhead Capital Management LLC now owns 2,104 shares of the company’s stock valued at $1,226,000 after buying an additional 15 shares during the period. Finally, Levin Capital Strategies L.P. boosted its position in Eli Lilly and Company by 3.8% during the fourth quarter. Levin Capital Strategies L.P. now owns 415 shares of the company’s stock valued at $242,000 after acquiring an additional 15 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 17,229 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $902.38, for a total value of $15,547,105.02. Following the transaction, the insider now owns 97,556,910 shares of the company’s stock, valued at $88,033,404,445.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the sale, the executive vice president now owns 25,428 shares in the company, valued at approximately $20,835,194.64. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 17,229 shares of Eli Lilly and Company stock in a transaction on Monday, June 24th. The stock was sold at an average price of $902.38, for a total transaction of $15,547,105.02. Following the sale, the insider now directly owns 97,556,910 shares of the company’s stock, valued at $88,033,404,445.80. The disclosure for this sale can be found here. Insiders have sold 789,704 shares of company stock worth $672,385,964 in the last three months. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Performance

LLY traded up $3.75 on Friday, hitting $912.79. The company’s stock had a trading volume of 430,449 shares, compared to its average volume of 2,913,400. The company’s 50 day simple moving average is $807.55 and its 200-day simple moving average is $735.35. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 12 month low of $434.34 and a 12 month high of $915.54. The firm has a market cap of $867.52 billion, a P/E ratio of 133.88, a price-to-earnings-growth ratio of 1.97 and a beta of 0.36.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period in the previous year, the company posted $1.62 EPS. The firm’s revenue for the quarter was up 26.0% compared to the same quarter last year. Analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on LLY shares. Truist Financial reissued a “buy” rating and issued a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Citigroup lifted their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Jefferies Financial Group increased their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday. Finally, JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $812.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.